Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.62 |
| ▸ | CDYL | Q9Y232 | 3/20 | 0.52 |
| ▸ | CBX7 | O95931 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.42 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 4/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2499643 | 0.90 | CDYL (0.60) | TP53MDM2CDYLCBX7SCN9A | |
| SCHEMBL3967434 | 0.88 | TP53 (0.51) | TP53MDM2CDYLCBX7ADAMTS5 | |
| SCHEMBL3967991 | 0.86 | ADAMTS5 (0.52) | TP53MDM2CDYLCBX7SCN9A | |
| SCHEMBL3966468 | 0.85 | BRD4 (0.52) | TP53MDM2BRD4POLBCASP6 | |
| SCHEMBL24280978 | 0.84 | KMT2A (0.59) | TP53MDM2CDYLCBX7SCN9A | |
| SCHEMBL24281862 | 0.81 | POLB (0.48) | TP53MDM2SCN9ABRD4POLB | |
| SCHEMBL27486481 | 0.79 | TP53 (0.44) | TP53MDM2CDYLCBX7SCN9A | |
| SCHEMBL2497114 | 0.79 | KDM4E (0.52) | TP53MDM2CDYLCBX7SCN9A | |
| SCHEMBL3973547 | 0.78 | POLB (0.49) | TP53MDM2BRD4POLBCASP6 | |
| SCHEMBL4590472 | 0.78 | CBX7 (0.52) | TP53MDM2CDYLCBX7ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1896412-A2 | OXINDOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136606-A2 | OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136606-A2 | OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293319-A1 | Oxindole derivatives | LUK KIM-CHUN | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293319-A1 | Oxindole derivatives | CCNI, OGFR, MKI67 | TP53 96/4885MDM2 759/4885CDYL 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.